anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Improvement of therapheutic and cosmetic properties.    2. Essence A shampoo contains in the form of anti-dandruff active ingredient ketoconazole or eluboil in an amount of 0,3-3 weight percent, surfactants, foaming agent, thickener, preservatives, acid, base or buffer sufficient for the pH regulation and antioxidant in form of butilated hydroxytoluene and butylated hydroxyanisole.             3. Field of application Perfume.    3 ind.cl.,    16 dep.cl., 4 tables.
Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies with subsequent immune complex deposition and tissue inflammation. The role of interferon (IFN) alpha in the development of SLE has been repeatedly documented. Vitamin D deficiency is common among lupus patients. Vitamin D is recognized as a regulator of immune response. This study will explore the impact of vitamin D3 supplementation on IFN alpha expression in SLE patients.

The study will last approximately 12 weeks and consist of three treatment groups: 1.) Participants will receive vitamin D3 2000 IU daily 2.) Participants will receive vitamin D3 4000 IU daily 3.) Participants will receive a vitamin D3 placebo daily. There will be four study visits for each participant. Visits will occur at screening, study entry, and Weeks 6 and 12. Physical examination, vital signs, and blood and urine tests will occur at all visits. For females of childbearing potential, a pregnancy test will be performed at screening and Week 6.
A method for measuring health metrics of a user is provided. A base of an electronic device is attached to the skin of the user. A housing of the electronic device is attached to the base, such that (i) the housing is secured to the base, and (ii) a window of the housing is positioned outside an opening in the base. One or more sensors within the housing generates first physiological data associated with the health metrics of the user through the housing window and the base opening. Second physiological data associated with the health metrics of the user is generated using a set of electrodes positioned outside of the housing. The set of electrodes are coupled to the base, and the set of electrodes facilitate movement of electrical signals between the skin of the user and a sensor printed circuit board within the housing of the electronic device.
PURPOSE: A patient recall method is provided to generate a patient recall model based on patient and treatment data, and to recall the patient according to date, a method and contents defined in the patient recall model. CONSTITUTION: A main server, plural servers installed at hospitals, and a server system controlling the servers are constructed(S10). A patient management database, linked to the main server, is constructed by storing name, sex, age, disease history, a contact point and others of the patient(S20). A treatment management database, also linked to the main server, is constructed(S30). The main server generates the first patient recall model based on the patient data stored at the patient management database(S40), and generates the second patient recall model based on the patient data stored at the treatment management database(S50). The main server notifies the patient of the recall contents by using the contact point stored at the patient management database, and checks whether the patient visits a hospital according to the notified recall contents(S60). The main server generates the recall result data(S70).
This group consists of 18 subjects who have chronic pain conditions treated with an opioid regimen. Subjects were randomized to receive a placebo treatment during the study. They were given an intravenous infusion of 50 ml normal saline over 30 minutes.
OBJECTIVES: The main aim of this study was to describe nutrition provision in Australian and New Zealand (ANZ) pediatric intensive care units (PICUs), including mode of nutrition and adequacy of enteral nutrition (EN) to PICU day 28. Secondary aims were to determine the proportion of children undergoing dietetics assessment, the average time to this intervention, and the methods for estimation of energy and protein requirements.
METHODS: This observational study was conducted in all ANZ tertiary-affiliated specialist PICUs. All children ≤18 y of age admitted to the PICU over a 2-wk period and remaining for ≥48 h were included. Data were collected on days 1 to 7, 14, 21, and 28 (unless discharged prior). Data points included oral intake, EN and parenteral nutrition support, estimated energy and protein adequacy, and dietetics assessment details.
RESULTS: We enrolled 141 children, of which 79 were boys (56%) and 84 were <2 y of age (60%). Thirty children (73%) received solely EN on day 7 with documented energy and protein targets for 22 (73%). Of these children, 14 (64%) received <75% of their estimated requirements. A dietetics assessment was provided to 80 children (57%), and was significantly higher in those remaining in the PICU beyond the median length of stay (41% in patients staying ≤4.6 d versus 72% in those staying >4.6 d; P < 0.001).
CONCLUSIONS: This prospective study of nutrition provision across ANZ PICUs identified important areas for improvement, particularly in EN adequacy and nutrition assessment. Further research to optimize nutrition provision in this setting is urgently needed.
Romidepsin was evaluated in 2 multicenter, single-arm clinical studies in patients with CTCL (Study 1 [NCT00106431] and Study 2 [NCT00007345]). Overall, 167 patients with CTCL were treated in the US, Europe, and Australia. Study 1 included 96 patients with confirmed CTCL after failure of at least 1 prior systemic therapy. Study 2 included 71 patients with a primary diagnosis of CTCL who received at least 2 prior skin directed therapies or one or more systemic therapies. Patients were treated with romidepsin at a starting dose of 14 mg/m2 infused over 4 hours on days 1, 8, and 15 every 28 days.

In both studies, patients could be treated until disease progression at the discretion of the investigator and local regulators. Objective disease response was evaluated according to a composite endpoint that included assessments of skin involvement, lymph node and visceral involvement, and abnormal circulating T-cells (“Sézary cells”).

The primary efficacy endpoint for both studies was overall objective disease response rate (ORR) based on the investigator assessments, and was defined as the proportion of patients with confirmed complete response (CR) or partial response (PR). CR was defined as no evidence of disease and PR as ≥ 50% improvement in disease. Secondary endpoints in both studies included duration of response and time to response.

Baseline Patient Characteristics

Demographic and disease characteristics of the patients in Study 1 and Study 2 are provided in Table 3.

Clinical Results

Efficacy outcomes for CTCL patients are provided in Table 4. Median time to first response was 2 months (range 1 to 6) in both studies. Median time to CR was 4 months in Study 1 and 6 months in Study 2 (range 2 to 9).
Participants will receive treatment with durvalumab + etoposide and either cisplatin or carboplatin (EP) for 4 to 6 cycles. Durvalumab will be administered at a dose of 1500 mg every 3 weeks (Q3W) with first-line chemotherapy (EP) and will continue to be administered as monotherapy every 4 weeks (Q4W) post-chemotherapy until progressive disease (PD). Prophylactic cranial irradiation (PCI) is allowed at the investigators' discretion as per SoC guidance for ES-SCLC. Patients will attend a safety follow up visit 90 days after last dose of durvalumab.
Probenecid is a uricosuric and renal tubular blocking agent. It inhibits the tubular reabsorption of urate, thus increasing the urinary excretion of uric acid and decreasing serum urate levels. Effective uricosuria reduces the miscible urate pool, retards urate deposition, and promotes resorption of urate deposits.

Probenecid inhibits the tubular secretion of penicillin and usually increases penicillin plasma levels by any route the antibiotic is given. A 2-fold to 4-fold elevation has been demonstrated for various penicillins.

Probenecid has also been reported to inhibit the renal transport of many other compounds including aminohippuric acid (PAH), aminosalicylic acid (PAS), indomethacin, sodium iodomethamate and related iodinated organic acids, 17-ketosteroids, pantothenic acid, phenolsulfonphthalein (PSP), sulfonamides, and sulfonylureas. See also Drug Interactions.

Probenecid decreases both hepatic and renal excretion of sulfobromophthalein (BSP). The tubular reabsorption of phosphorus is inhibited in hypoparathyroid but not in euparathyroid individuals.

Probenecid does not influence plasma concentrations of salicylates, nor the excretion of streptomycin, chloramphenicol, chlortetracycline, oxytetracycline, or neomycin.
<P>PROBLEM TO BE SOLVED: To prepare a cosmetic in which raw materials difficultly soluble both in an oily ingredient and in an aqueous ingredient are uniformly emulsified or dispersed.  <P>SOLUTION: This cosmetic comprises (1) a compound represented by formula (1) and (2) a triterpene derivative and/or a sphingosine derivative. It is desirable that the compound represented by formula (1) is phenoxyethanol or phenethyl alcohol. It is desirable that the triterepene derivative is at least one member selected from among a triterepenol glycoside, a triterpene acid, and a triterpene acid ester. It is desirable that the sphigosine derivative is a sphingoglycolipid or a sphingophospholipid. It is desirable that the cosmetic is in a form not substantially containing an alcohol. In formula (1), A is oxygen atom or methylene group; and R is a 1 to 4C alkylene group.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Receptor blocker (antagonist) drugs which suppress the binding of the D4 class of leukotriene molecules to leukotriene receptors can reduce the frequency and severity of recurrent primary headaches, including migraine and cluster headaches. Various LTD4 receptor blockers are commercially available, including montelukast and zafirlukast. In the past, these drugs have been used to treat asthma. During human clinical trials on asthma patients, headaches were one of the most commonly reported side effects of each of those two drugs; therefore, they apparently were never tested as agents which might prevent or reduce migraine or cluster headaches. However, it has been shown that in at least some patients who suffer from acute recurrent migraines, LTD4 receptor blockers can greatly reduce the frequency, duration, and/or severity of their headaches, when taken chronically on a daily basis. Tests also indicate that LTD4 receptor blockers can effectively treat onset of acute migraine or cluster headaches, and can also be combined with a triptan drug to achieve a synergistic effect against acute headaches.
PURPOSE:To obtain the paste compsn. which has sufficient water repellency and adequate consistency and has excellent operability by preparing the paste compsn. contg. 70 to 40wt.% at least one kind of oily liquids and 30 to 60wt.% powder of at least one kind of metallic compds. CONSTITUTION:The component A of the paste compsn. is the oily liquid selected from a group consisting of silicone oil, liquid paraffin, polybudene and fatty acid. The component A is incorporated into the paste compsn. of this invention at 70 to 40wt.% based on the total weight of the compsn. The component B of the paste compsn. is the powder of the metallic compds. of oxides, such as titanium oxide, zinc oxide, magnesium oxide, aluminum oxide, silicon dioxide, carbonates, such as calcium carbonate, magnesium carbonate and bismuth carbonate and sulfates, such as calcium sulfate. The component B is incorporated into the paste compsn. of this invention at 30 to 60wt.% based on the total weight of the compsn.
Aligned with the USAID HEARD (Health Evaluation and Applied Research Development) purpose to leverage global partnerships to generate, synthesize, and use evidence to improve program implementation in low and middle-income countries, the proposed study will examine the impact and implementation of the Journey of Life (JoL) intervention in a humanitarian setting. The JoL intervention aims to provide psychosocial support to adults and galvanize caregivers to develop action plans for child protection in their communities. The proposed research will involve an analysis of effect sizes for mental health, functioning, social support, child protection behaviors, parenting attitudes and behaviors, and experiences of intimate partner violence. The research also aims to interrogate implementation strategies that are useful within humanitarian contexts through qualitative key informant interviews and focus group discussions. Assessments include baseline and follow up data collection to measure effect sizes and assess implementation strategy components. The study aims are to: (1) assess the impact of JoL on child protection indicators, (2) examine the effects of JoL on behavioral health functioning (i.e. mental health, social support, and functioning)
Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.
Use of a water-soluble copolymer as an agent for improving UV-absorbent capabilities of sun protection compositions comprising particles of titanium dioxide and/or zinc oxide, is claimed. The copolymer comprises (a) at least one acrylic acid monomer and methacrylic acid monomer and/or their salt, and (b) at least one monomer (I), and has a molecular weight of 25000-50000000 g/mole determined by gel permeation chromatography. Use of a water-soluble copolymer as an agent for improving UV-absorbent capabilities of sun protection compositions comprising particles of titanium dioxide and/or zinc oxide, is claimed. The copolymer comprises (a) at least one acrylic acid monomer and methacrylic acid monomer and/or their salt, and (b) at least one monomer of formula (R-X-R1) (I), and has a molecular weight of 60000-50000000 g/mole determined by gel permeation chromatography. R : polymerizable unsaturated function, preferably methacrylate (preferred), acrylate, methacrylurethane, vinyl or allyl; R1 : H or 1-4C-alkyl, preferably H or CH 3; X : structure comprising ethylene oxide n units and propylene oxide m units, disposed randomly or regularly; and m, n : 2, preferably 0-100. An independent claim is included for a solar protection composition comprising, in a support, 0.1-50 wt.% of titanium dioxide and/or zinc oxide, and UV radiation filtering agents and the copolymer.
INTRODUCTION: The inverse problem of electrocardiography describes non-invasively the electrical activity of the heart using potential recordings from tens to hundreds of torso electrodes. Regrettably, the use of numerous electrodes poses a challenge to its integration into routine clinical practice.
METHODS: Optimal electrode placements, ranging from 8 to 112 electrodes, were derived from the singular values of the transfer matrices computed for all feasible positions of a single dipole cardiac source across 12 patients with unique geometrical characteristics from the Bratislava dataset. The transfer matrices were computed using the boundary element method. Subsequently, these optimal electrode placements were used to compute the inverse solution for localizing the origin of premature ventricular contraction (PVC) with a single dipole cardiac source. The localization error (LE) was computed as the Euclidean distance between the true PVC origin, obtained through an invasive radiofrequency ablation, and the inverse solution. This enabled a direct comparison of LE computed for each optimal electrode placement with that from the full 128-electrode set.
RESULTS: Results showed that subsets of electrodes, particularly 32 to 112, provided comparable localization accuracy (LE of 30.5 ± 15.0 mm and 26.8 ± 12.6 mm) to the full 128-electrode set (LE of 27.2 ± 11.5 mm). High errors were observed with 8 and 16-electrode placements (LE of 48.6 ± 21.3 mm and 41.0 ± 18.3 mm).
CONCLUSION: Precise PVC localization can be achieved using strategically positioned subsets of electrodes, offering advantages in reduced preparation time, enhanced patient comfort, and improved cost-effectiveness of body surface potential mapping.
Corneal neovascularization (CNV) is a major cause of blindness worldwide. However, the recent drug treatment is limited by repeated administration and low drug bioavailability. In this work, SU6668 (an inhibitor of receptor tyrosine kinases) and indocyanine green (ICG) are loaded onto poly(lactic-co-glycolic acid) (PLGA) nanoparticles, and then coated with anti-VEGFR2 single chain antibody (AbVr2 scFv) genetically engineered cell membrane vesicles. The nanomedicine is delivered via eye drops, and the hyperthermia induced by laser irradiation could block the blood vessels. Meanwhile, the photothermal effect can also cause the degradation of nanomaterials and release chemotherapeutic drugs in the blocked area, thereby continuously inhibit the neovascularization. Furthermore, SU6668 could inhibit the expression of heat shock protein 70 (HSP70), promoting the cell death induced by photothermal effect. In conclusion, the combination of photothermal and chemotherapy drugs provides a novel, effective and safe approach for the treatment of CNV.
Myocardial infarction is a cardiovascular disease characterized by a high incidence rate and mortality. It leads to various cardiac pathophysiological changes, including ischemia/reperfusion injury, inflammation, fibrosis, and ventricular remodeling, which ultimately result in heart failure and pose a significant threat to global health. Although clinical reperfusion therapies and conventional pharmacological interventions improve emergency survival rates and short-term prognoses, they are still limited in providing long-lasting improvements in cardiac function or reversing pathological progression. Recently, cardiac patches have gained considerable attention as a promising therapy for myocardial infarction. These patches consist of scaffolds or loaded therapeutic agents that provide mechanical reinforcement, synchronous electrical conduction, and localized delivery within the infarct zone to promote cardiac restoration. This review elucidates the pathophysiological progression from myocardial infarction to heart failure, highlighting therapeutic targets and various cardiac patches. The review considers the primary scaffold materials, including synthetic, natural, and conductive materials, and the prevalent fabrication techniques and optimal properties of the patch, as well as advanced delivery strategies. Last, the current limitations and prospects of cardiac patch research are considered, with the goal of shedding light on innovative products poised for clinical application.
Most updated international guidelines recommend Coronary Computed Tomography Angiography (CCTA) as the initial test to rule out coronary artery disease (CAD). CCTA should also be considered an alternative to invasive coronary angiography (ICA) for non-diagnostic or indeterminate results of other noninvasive tests. Thanks to spatial and temporal resolution increase, CCTA is now considered in an extensive range of pre-test probability (PTP), from 5% to 90%. Indeed, the accuracy of CCTA for identifying patients with at least one significant coronary arterial stenosis, defined as moderate (≥50%) by ICA, has reached almost 90%. Furthermore, CCTA and anatomical evaluation seem superior to stress testing for risk prediction among patients with at least moderate ischemia. As a result, CCTA has been recognized as the first-line diagnostic test for most patients with suspected chronic coronary syndrome and even in some acute chest pain presentation.

Suppose CCTA serves as a gatekeeper for ICA because of its high negative predictive value and eventually will replace ICA in its diagnostic role, as hypothesized. In that case, it is pivotal to understand instances of discrepancies that are encountered in clinical practice. In addition, prior studies have primarily evaluated the performance of CCTA in identifying a ≥moderate coronary stenosis (i.e., ≥50% lumen narrowing) as compared with ICA. Instead, there is much less evidence of its ability to rule out severe coronary stenosis (i.e., ≥70% lumen narrowing). This is noteworthy because recent studies have shown that the anatomic severity of CAD has a strong prognostic impact, even more than ischemia. Finally, new techniques such as dynamic stress CT perfusion (stress-CTP) and fractional flow reserve CT derived (FFR-CT) emerged as potential strategies to combine anatomical and functional evaluation providing additional diagnostic accuracy.

Against this background, the investigators aim 1) to report the real word data on the performance of last-generation CCTA in identifying obstructive CAD (also considering different thresholds of stenosis, i.e., moderate or severe) and 2) to identify predictors of discrepancies. The investigators hope this study will help interpret CCTA findings in clinical practice and eventually refine the diagnostic algorithm for patients with obstructive CAD.
Individually titrate hydromorphone hydrochloride extended-release tablets to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving hydromorphone hydrochloride extended-release tablets to assess the maintenance of pain control, signs and symptoms of opioid withdrawal, and other adverse reactions, as well as to reassess for the development of addiction, abuse, or misuse [see Warnings and Precautions (5.1, 5.13)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During use of opioid therapy for an extended period of time, periodically reassess the continued need for opioid analgesics.

Plasma levels of hydromorphone hydrochloride extended-release tablets are sustained for 18 to 24 hours. Dosage adjustments of hydromorphone hydrochloride extended-release tablets may be made in increments of 4 to 8 mg every 3 to 4 days as needed to achieve adequate analgesia.

Patients who experience breakthrough pain may require a dose increase of hydromorphone hydrochloride extended-release tablets, or may need rescue medication with an appropriate dose of an immediate-release analgesic. If the level of pain increases after dose stabilization, attempt to identify the source of increased pain before increasing the hydromorphone hydrochloride extended-release tablets dose.

If after increasing the dosage, unacceptable opioid-related adverse reactions are observed (including an increase in pain after dosage increase), consider reducing the dosage [see Warnings and Precautions (5)]. Adjust the dose to obtain an appropriate balance between management of pain and opioid-related adverse reactions.